Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Inclusion Criteria: * One of the following histologically confirmed diagnoses: * Renal cell cancer * Clear cell histology * Metastatic or unresectable disease AND meets 1 of the following criteria: * Recurrent disease * Refractory to interleukin-2 (IL-2)- or interferon-based therapy * Previously untreated AND not a candidate for IL-2-based therapy * Colorectal, head and neck, pancreatic, or non-small cell lung cancer * Metastatic or unresectable disease * Progression after prior standard treatment * No evidence of CNS disease, including the following (part 2 only): * Primary brain tumor * Brain metastases * Paraffin embedded tumor blocks available * Performance status - ECOG 0-2 * Performance status - Karnofsky 60-100% * More than 12 weeks * Absolute neutrophil count ≥ 1,500 mm\^3 * Platelet count ≥ 100,000 mm\^3 * Bilirubin ≤ 1.5 mg/dL * AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastasis is present) * PTT and INR ≤ 1.5, unless receiving full-dose warfarin (part 2 only) * Creatinine ≤ 1.5 times ULN * Creatinine clearance ≥ 60 mL/min * Calcium \< 10 mg/dL (hypocalcemic agents allowed) * No proteinuria\* * Protein \< 1 g on 24-hour urine collection\* * No unstable angina pectoris * No cardiac arrhythmia * No symptomatic congestive heart failure * None of the following are allowed for part 2: * Myocardial infarction within the past 6 months * New York Heart Association class II-IV heart diseas…